Fycompa Oral Suspension Launched for Patients with Swallowing Difficulty

The oral suspension formulation is now available as a 0.5mg/mL strength in 340mL bottles
The oral suspension formulation is now available as a 0.5mg/mL strength in 340mL bottles

Eisai announced the availability of Fycompa (perampanel) Oral Suspension for use in patients who have difficulty swallowing tablets or prefer liquids. The oral suspension, which was recently approved, is a bioequivalent interchangeable alternative to Fycompa tablets

Fycompa is indicated as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy ≥12 years old. It is a non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist. The precise mechanism by which it exerts antiepileptic effects in humans has not been fully elucidated. 

Related Articles

Fycompa is a CIII controlled substance already available as 2mg, 4mg, 6mg, 8mg, 10mg, and 12mg strength tablets. The new oral suspension formulation is now available as a 0.5mg/mL strength in 340mL bottles with an adapter and syringes. 

For more information call (888) 274-2378 or visit Fycompa.com.

Loading links....